The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
Status:
Terminated
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This is a 15-month study with two phases. During the first 12-month phase of this study,
patients will be randomly assigned to receive either active study drug or placebo
(approximately half of all patients will be on active study drug, the other half on placebo).
The second phase is a 3-month randomized withdrawal period. For this phase approximately 10%
of the patients will remain on the active drug.